Torpy & All,
Just another thing that might be of interest to ACW investors is the ILAP accelerated pathway that was launched in the UK earlier this year. Another biotech I am invested in recently announced that this was awarded for their drug candidate going into a Ph3, however this pathway is also for earlier drug development also.
I see no reason that Xanamem would not be a good candidate for ILAP Accelerated pathway for Regulatory Approval. Article below with more information & a lot of articles out on this, big news in the UK:
https://www.miragenews.com/mhra-innovative-licensing-and-access-pathway-is-open-for-business/
Just a thought.
Under valued stock, page-95
-
- There are more pages in this discussion • 82 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.6¢ |
Change
-0.001(3.70%) |
Mkt cap ! $70.50M | |||
| Open | High | Low | Value | Volume |
| 2.6¢ | 2.8¢ | 2.6¢ | $324.6K | 12.16M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 31 | 7020618 | 2.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.6¢ | 372676 | 2 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| ACW (ASX) Chart |